EWTX Edgewise Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
0.355
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Edgewise Therapeutics reports $1.17B third quarter 2026 net income after sevasemten sale
Edgewise Therapeutics shifted to significant profitability in the third quarter of 2026, driven entirely by a massive one-time gain from the divestiture of its...
Edgewise Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Edgewise Therapeutics is projected to post a Q3 2026 loss of $0.55 per share on revenue of $119.23 million, with its current stock price of $37.68 trading...